Close Menu

NEW YORK (GenomeWeb) – Sequenta said this week that biopharmaceutical firm Celgene and others have made an equity investment into the company. Sequenta told GenomeWeb Daily News that the investment is a Series D financing but declined to disclose the amount or identify the other investors. The funding will support incorporation of Sequenta's ClonoSight test into clinical trials of medicines in development for blood cancers. It also will go toward development of new clinical diagnostics based on the company's LymphoSight platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.